All In Biotech

Drug Trial Radar · NCT07339514

A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease.

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Feb 11, 2025

Primary completion

Apr 1, 2026

Study completion May 30, 2026

Sponsor

Lead sponsor
ExoRNA BioscienceIndustry
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose escalation and expansion clinical study to evaluate the safety, tolerability, PK profile and preliminary efficacy of ER2001 Injection vs. placebo in subjects with definitive diagnosis of early manifest HD. The study consists of a dose escalation phase (Part A, an open-label without placebo, which will be carried out firstly) and a dose expansion phase (Part B,randomized, blinded, placebo-controlled), both of which include a screening period (4 week prior to the first administration), a treatment period (for 6 consecutive weeks, once a week \[QW\] for 6 weeks), and a safety follow-up period (24 weeks).

Conditions

  • Huntington Disease

Interventions

  • ER2001 intravenous injectionDrug

    The drug dose is 0.08mg/kg, or 0.32mg/kg. The planned duration of each patient's treatment is 6 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 2, 3, 4, 5, and 6.

  • PlaceboDrug

    Placebo Injection, The planned duration of the treatment is 6 weeks, and Placebo will be administrated intravenously at the first day of weeks 1, 2, 3, 4, 5, and 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: Approximately 7.5 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.